Diagnosis of Primary Aldosteronism without Discontinuation of Interfering Antihypertensive Medications.

Purpose of review

One of the challenges in the diagnosis and management of primary aldosteronism (PA), the most common type of secondary hypertension with curative potential, is the modification of antihypertensive medications. We seek to explore whether these medications can be continued during the diagnostic process of PA to minimize the duration and risks associated with medication adjustments.

Recent findings

We searched PubMed for eligible original literature between 1990 and 2024 using the following keywords: (screening) AND (primary aldosteronism); (confirmatory) AND (primary aldosteronism); (adrenal vein sampling) AND primary aldosteronism). Some recent studies support the feasibility of PA-related tests and even adrenal vein sampling (AVS) without the need to discontinue antihypertensive medications in certain cases. In this review, we propose a management approach that considers the specific effects of antihypertensive medications on the RAAS axis and the patient's disease phenotype. Based on this, we suggest a strategy that enables the diagnosis of PA in certain patients without discontinuing their antihypertensive medications.

References:

• Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol. 2020;75(16):1913–22. https://doi.org/10.1016/j.jacc.2020.02.052 .
• Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary Aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811–20. https://doi.org/10.1016/j.jacc.2017.01.052 .
• Brown M, Siddiqui J, Calhoun MA et al. D,. The Unrecognized Prevalence of Primary Aldosteronism. Ann Intern Med. Published online May 26, 2020. https://doi.org/10.7326/M20-0065
• Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243–8. https://doi.org/10.1016/j.jacc.2005.01.015 .
• Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50. https://doi.org/10.1016/S2213-8587(17)30319-4 .